Revolution Medicines and Moderna prove that high-risk bets on undruggable targets can finally work - here's what it means for biotech investors and pharma execs.

The smart ring maker’s rise reflects a broader shift toward wearable health tracking, with implications for employers, insurers, and the future of preventive care.

Beijing's health regulators have approved a wave of brain-computer interface products this year, as domestic startups target paralysis, Alzheimer's, and depression - putting China in direct competition with Elon Musk's Neuralink.

The national health insurance nod could accelerate adoption of regenerative therapies for heart disease, opening a new era for cell-based medicine.

George Arison is pushing AI, healthcare, and long-distance matchmaking to turn Grindr into a super app - but investors are still skeptical.

The CEO's secretive in-house casting operation could reshape power markets, yet the fuel source is drawing legal and health scrutiny.